Pomerantz Law Firm Announces the Filing of a Class Action Against SSR Mining Inc. - SSRM

Pomerantz LLP announces that a class action lawsuit has been filed against SSR Mining Inc. (“SSR” or the “Company”) (NASDAQ: SSRM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether SSR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until May 17, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired SSR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On February 13, 2024, SSR issued a press release “announc[ing] a suspension of operations at the Çöpler mine as a result of a large slip on the heap leach pad.  This event occurred in the morning of February 13, 2024 at approximately 6:30 am EST, and all operations at Çöpler have been suspended as a result.”  That same day, Reuters published an article reporting that a landslide at SSR’s Çöpler mine “left at least nine miners missing[.]” 

On this news, SSR’s stock price fell $5.22 per share, or 53.7%, to close at $4.50 per share on February 13, 2024.  In the days following the incident, various media outlets reported that several Company employees had been detained by Turkish authorities. 

On February 18, 2024, SSR issued a press release in which the Company “acknowledge[d] that several of our team members are facing charges in relation to the recent incident[.]” 

On this news, SSR’s stock price fell $0.40 per share, or 8.15%, over two trading sessions, to close at $4.51 per share on February 21, 2024. 

Finally, on February 27, 2024, SSR conducted its earnings call for the fourth quarter of 2024, during which it acknowledged that the incident at the Çöpler mine “will have an impact on our financial results in 2024.” 

On this news, SSR’s stock price fell $0.37 per share, or 7.93%, to close at $4.29 per share on February 28, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.   

Attorney advertising.  Prior results do not guarantee similar outcomes.    

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines – EXAI

Pomerantz LLP announces that a class action lawsuit has been filed against Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) and certain officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 24-cv-05692, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Exscientia securities between March 23, 2022, and Febraury 12, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

 

If you are a shareholder who purchased or otherwise acquired Exscientia securities during the Class Period, you have until June 25, 2024, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

            Exscientia in an artificial intelligence (“AI”) driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.

 

At all relevant times, the Company purported to “maintain[] the highest standards of business conduct and ethics” and, to that end, adopted a Code of Business Conduct and Ethics which applies to all of its employees, officers and directors, including former Chief Executive Officer (“CEO”) and Director Defendant Andrew Hopkins (“Hopkins”), former Chairman of the Company’s Board of Directors (the “Board”) Defendant David Nicholson (“Nicholson”), and all other executive and senior officers.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendant Hopkins had engaged in improper relationships with employees that were inconsistent with the Company’s standards and values; (ii) Defendant Nicholson had prior knowledge of Defendant Hopkins’s relationships and had improperly addressed Hopkins’s misconduct without consulting the Board; (iii) the Company’s maintenance and enforcement of its Code of Business Conduct and Ethics was inadequate to safeguard against the foregoing conduct; (iv) the foregoing failures subjected the Company to a heightened risk of disruptive leadership transitions and/or reputational harm; and (v) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

 

            On February 13, 2024, Exscientia issued a press release “announc[ing] that its Board of Directors (the ‘Board’) has decided to terminate the employment of [Defendant] Hopkins as the Company’s [CEO] and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.”  The press release further revealed that the Board’s decision was taken following an investigation which found that Defendant Hopkins had “engaged in relationships with two employees that the Board determined were inappropriate and inconsistent with the Company’s standards and values.”  In addition, the press release indicated that during the course of the investigation, the Board learned that “[Defendant] Nicholson [. . .] had prior knowledge of the existence of the earlier of Dr. Hopkins’ relationships and had addressed the situation directly, and with the involvement of other outside counsel, rather than in consultation with the Board,” and “[f]ollowing discussions with the Board, on February 12, 2024 Dr. Nicholson tendered his resignation from his positions with the Company.”

 

On this news, Exscientia’s stock price fell $1.72 per share, or 22.9%, to close at $5.79 per share on February 13, 2024.

 

As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

 

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Rivian Automotive, Inc. of Class Action Lawsuit and Upcoming Deadlines – RIVN

Pomerantz LLP announces that a class action lawsuit has been filed against Rivian Automotive, Inc. (“Rivian” or the “Company”) (NASDAQ: RIVN) and certain officers.   The class action, filed in the United States District Court for the Central District of Califorina, and docketed under 24-cv-03269, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Rivian securities between March 1, 2023 and February 21, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

 

If you are a shareholder who purchased or otherwise acquired Rivian securities during the Class Period, you have until June 18, 2024, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

            Rivian, together with its subsidiaries, designs, develops, manufactures, and sells electric vehicles and accessories.  The Company sells its products directly to customers in the consumer and commercial markets.

 

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Rivian had overstated demand for its products, as well as its ability to withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s business was experiencing reduced demand and increased customer cancellations as a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order bank had significantly deteriorated; (iv) all the foregoing was likely to, and did, negatively impact the Company’s anticipated earnings and vehicle production targets for 2024; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

            On February 21, 2024, Rivian announced its fourth quarter and full year 2023 financial results.  Among other items, Rivian announced that it expected to produce 57,000 vehicles in 2024, significantly lower than analyst expectations of 80,000 vehicles.  The Company further forecasted an adjusted earnings before interest, taxes, depreciation, and amortization loss of $2.7 billion for full year 2024, compared to analyst expectations of $2.59 billion, and announced plans to cut 10% of salaried staff, citing economic uncertainty.  On the subsequent earnings call to discuss these results, Rivian’s Chief Executive Officer, Defendant Robert J. Scaringe, revealed that “historically high interest rates . . . ha[ve] negatively impacted demand” and “[o]ur order bank has notably reduced overtime . . . along with the impact of cancellations due to both the macroenvironment and [various] customer factors” such as “delivery timing, location of order, monthly payments, and customer readiness.”

 

            On this news, Rivian’s stock price fell $3.94 per share, or 25.6%, to close at $11.45 per share on February 22, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

 

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in VinFast Auto Ltd. of Class Action Lawsuit and Upcoming Deadlines – VFS

Pomerantz LLP announces that a class action lawsuit has been filed against VinFast Auto Ltd.  (“VinFast” or the “Company”) f/k/a Black Spade Acquisition Co., (“Black Spade”) (NASDAQ: VFS) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 24-cv-02750, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired VinFast securities: (a) pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the merger (“Merger”) consummated on August 14, 2023 by and among the Company, Black Spade, and Nuevo Tech Limited, a Cayman Islands exempted company and wholly owned subsidiary of the Company (“Merger Sub”); and/or (b) between August 15, 2023 and January 17 2024, both dates inclusive (the “Class Period”).  Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).

 

If you are a shareholder who purchased or otherwise acquired VinFast securities during the Class Period, you have until June 11, 2024 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

                VinFast describes itself as “an innovative, full-scale mobility platform focused primarily on designing and manufacturing premium EVs (“electric vehicles”), e-scooters, and e-buses.”  Founded and headquartered in Vietnam, the Company has since expanded its sales and operations into other markets, including Southeast Asia, North America, and Europe.  Prior to the Merger, the Company operated as a publicly traded special purpose acquisition company, or a development stage company that has no specific business plan or purpose or has indicated that its business plan is to engage in a merger or acquisition with an unidentified company or companies, other entity, or person.

 

                On May 12, 2023, VinFast announced that it had entered into a business combination with Black Spade, which purportedly “runs a global portfolio consisting of a wide spectrum of cross-border investments, and consistently seeks to add new investment projects and opportunities to its portfolio.”

 

                On June 15, 2023, VinFast filed a registration statement (“Registration Statement”) on Form F-4 with the SEC in connection with the Merger, which, after several amendments, was declared effective by the SEC on July 28, 2023.

 

                Also on July 28, 2023, the Company filed a joint prospectus and proxy statement (the “Prospectus” and, together with the Registration Statement, the “Offering Documents”) on Form 424B3 with the SEC in connection with the Merger, which incorporated and formed part of the Registration Statement.

 

                On August 14, 2023, the Company consummated the Merger whereby, among other things, Merger Sub merged with and into Black Spade, with Black Spade surviving the transaction as a wholly owned subsidiary of the Company.

 

                On August 15, 2023, the Company’s ordinary shares and warrants began publicly trading on the Nasdaq Global Select Market (“NASDAQ”) under the ticker symbols “VFS” and “VFSWW,” respectively.

 

                Leading up to and following the Merger, VinFast repeatedly represented that the Company was focused on “achieving operational efficiency and technological integration” and “continuously improv[ing] [its] processes to deliver world-class products.”  Indeed, the Company touted that that it possessed such strengths as a “Comprehensive Mobility Ecosystem with Strategic Focus on High Growth Segments” and a “Demonstrated Speed to Market and Ability to Execute.”  In particular, the Company indicated that it aimed to accomplish its long-term growth strategies by, in part, “continu[ing] growing [its] global footprint into areas where [it] expect[ed] high [electric vehicle (“EV”)] demand growth,” and stated that it expected “[d]eliveries of vehicles to be between 40,000 and 50,000 vehicles in FY2023.”

 

The Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation.  Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) VinFast lacked sufficient capital to execute its purported growth strategy; (ii) VinFast would be unable to meet its 2023 delivery targets; (iii) accordingly, VinFast had overstated the strength of its business model and operational capabilities, as well as its post-Merger business and/or financial prospects; and (iv) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

 

                On October 15, 2023, Bloomberg published an article entitled “VinFast to Expand Into Southeast Asia, Raise More Capital.”  The article discussed the Company’s plans to aggressively move into Southeast Asian markets, starting with Indonesia, and revealed that, according to VinFast’s Chief Executive Officer Le Thi Thu Thuy, the Company would need to raise “a lot of capital” in order to fuel its global expansion plans and would “rely on [financial] support from parent company Vingroup JSC and its founder Pham Nhat Vuong in the next 18 months.”

 

                On this news, VinFast’s ordinary share price fell $1.45 per share, or 18.17%, to close at $6.53 per share on October 16, 2023.

 

                Then, on January 18, 2024, VinFast issued a press release announcing its Q4 2023 deliveries.  The press release revealed that the Company delivered a total of 34,855 EVs in 2023, falling well short of its annual deliveries target of 40,000-50,000 units.  In response, several market analysts commented on the Company’s disappointing announcement.  For example, Barrons published an article entitled “Vietnamese Carmaker Vinfast Misses 2023 EVs Sales Target” which noted that VinFast was “hoping to compete with EV giants such as Tesla” and was “listed on the Nasdaq in August, hitting headlines around the world as its valuation skyrocketed and then crashed.”

 

                On this news, VinFast’s ordinary share price fell $0.13 per share, or 2.25%, to close at $5.64 per share on January 18, 2024, representing a total decline of 84.78% from the Company’s first post-Merger closing stock price of $37.06 per share on August 15, 2023 (the “Initial Closing Price”).

 

As of the time this Complaint was filed, VinFast’s ordinary shares were trading significantly below their Initial Closing Price and continue to trade below their initial value from the Merger, damaging investors.

 

As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.   

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

 

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-02613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

 

If you are a shareholder who purchased or otherwise acquired Checkpoint securities during the Class Period, you have until June 4, 2024 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

            Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the U.S. and internationally.  The Company relies on third-party contract manufacturers to, inter alia, conduct its preclinical and clinical studies and trials, as well as to complete commercial and pre-commercial manufacturing.

 

            Checkpoint’s lead antibody product candidate is cosibelimab for the treatment of selected recurrent or metastatic cancers.  In January 2023, Checkpoint submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for the approval of cosibelimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or radiation (the “cosibelimab BLA”).

 

            The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Checkpoint had overstated its oversight of, and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers; (ii) accordingly, there were one or more issues with the Company’s third-party contract manufacturing organization (“CMO”) for cosibelimab; (iii) all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form; (iv) as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

            On December 18, 2023, Checkpoint issued a press release disclosing that the FDA had not approved the cosibelimab BLA as a treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation.  In particular, the Company announced “that the [FDA] has issued a complete response letter (‘CRL’) for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who are not candidates for curative surgery or radiation.”  The Company stated that “[t]he CRL . . . cites findings that arose during a multi-sponsor inspection of Checkpoint’s third-party [CMO] as approvability issues to address in a resubmission.”

 

On this news, Checkpoint’s stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

 

 

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in HireRight Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines – HRT

Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.   The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 24-cv-00371, is on behalf of all those who purchased or otherwise acquired HireRight securities pursuant and/or traceable to the Offering Documents (defined below) issued in connection with HireRight’s October 2021 initial public offering (the “IPO” or “Offering”).  Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the “Securities Act”).

 

If you are a shareholder who purchased or otherwise acquired HireRight securities during the Class Period, you have until June 3, 2024 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

            HireRight provides technology-driven workforce risk management and compliance solutions to a customer base characterized as a “diverse set of organizations, from large-scale multinational businesses to small and medium-sized businesses, across a broad range of industries.”  The Company offers background screening, verification, identification, monitoring, and drug and health screening services for customers under the HireRight brand name and boasts a purportedly “robust pipeline of opportunities developed by [its] sales team to continue to attract new customers and take share in the market.” 

 

            On October 6, 2021, HireRight filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (“SEC”) in connection with the IPO, which, after an amendment, was declared effective by the SEC on October 28, 2021 (the “Registration Statement”).

 

            On November 1, 2021, HireRight filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the “Prospectus” and, collectively with the Registration Statement, the “Offering Documents”).

 

            That same day, pursuant to the Offering Documents, HireRight’s common stock began publicly trading on the New York Stock Exchange under the ticker symbol HRT.

 

            Pursuant to the Offering Documents, HireRight issued approximately 22. million shares of its common stock to the public at the Offering price of $19.00 per share for proceeds to the Company of approximately $399 million after applicable underwriting discounts and commissions, and before expenses.

 

            The Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and was not prepared in accordance with the rules and regulations governing its preparation.  Specifically, the Offering Documents made false and/or misleading statements and/or failed to disclose that: (i) HireRight was exposed to customers with significant employment and hiring risk and the Company derived greater revenue growth from existing client hiring than from new client hiring; (ii) as a result, the Company’s revenue growth was unsustainable to the extent that it relied on the stability of its current customers’ hiring and/or the profitability of securing new customers; (iii) accordingly, HireRight had overstated its post-IPO business and/or prospects; and (iv) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

 

            On January 19, 2023, Stifel, a brokerage and investment banking firm, downgraded HireRight’s stock from a Hold to a Buy, prompting several market analysts to issue publications discussing the downgrade.  For example, Seeking Alpha reported that Stifel found HireRight to be exposed to large technology firms where there is more acute employment and hiring risk, and that more of the Company's growth comes from existing client hiring than from new.

           

On this news, HireRight’s stock price fell $0.88 per share, or 7.5%, to close at $10.75 per share on January 19, 2023.

 

            At the time of this Complaint, HireRight’s common stock continue to trade below the $19.00 per share IPO price.

 

As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of HireRight’s securities, Plaintiff and other Class members have suffered significant losses and damages.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

 

 

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Super Micro Computer, Inc. - SMCI

Pomerantz LLP is investigating claims on behalf of investors of  Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NASDAQ: SMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

 

The investigation concerns whether Super Micro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

 

[Click here for information about joining the class action]

 

On March 17, 2024, the Wall Street Journal published an article entitled “Meet the Tech Company That Had a Better Year Than Nvidia”, reporting that Super Micro “has become a go-to supplier for companies and governments eager to participate in the AI boom” and reporting that the Company’s Chief Executive Officer (“CEO”) Charles Liang “said his goal was to be producing 5,000 racks of servers a month . . . by the middle of this year.”  On March 19, 2024, in a filing with the U.S. Securities and Exchange Commission, Super Micro issued a clarification regarding CEO Liang’s comments, stating that the Company “is continuing to work towards achieving Mr. Liang’s stated capacity goal in the stated timeframe, but the Company’s ability to do so is dependent on its ability to address supply chain constraints on AI platform-related components (including GPUs, CPUs, networking cards and high performance memory), its ability to raise sufficient capital to fund this growth, continued demand for its products, including its AI-compatible servers, as well as other operational, strategic and industry risks”. 

 

Following Super Micro’s clarification, the Company’s stock price fell $89.71 per share, or 8.96%, to close at $910.97 per share on March 19, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.   

 

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Bancorp, Inc. - TBBK

NEW March 25, 2024 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  The Bancorp, Inc. (“TBBK” or the “Company”) (NASDAQ: TBBK).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

 

The investigation concerns whether TBBK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

 

[Click here for information about joining the class action]

 

On March 21, 2024, TBBK shares sharply declined after activist short seller Culper Research (“Culper”) took aim at the bank holding company, alleging that TBBK has misrepresented the quality of its real estate bridge loan (“REBL”) portfolio and contending that TBBK’s related loss reserves are woefully inadequate.  The report, entitled “The Bancorp Inc. (NASDAQ TBBK): Bridge to Nowhere,” was based on Culper's loan-by-loan analysis, visits to 21 different TBBK-funded properties in the prior 2 weeks, conversations with former TBBK employees including a REBL underwriter, and conversations with several TBBK borrowers/syndicators.  Culper further stated that “TBBK's book also appears rife with unsophisticated syndicated borrowers[]” with “‘get rich quick dreams’ who believed that they could easily rehab units, fill them with tenants, increase rents, and cash out for quick ‘passive’ returns.”  But, the analyst continued, “for these properties, none of these things have happened: costs have skyrocketed, vacancies remain high, rents have remained relatively stagnant, and interest rates have more than doubled.”  In Culper's view “TBBK's $4.7 million in reserves, at just 0.24% of its REBL book, are a total farce.” 

 

On this news, TBBK’s stock price fell $3.63 per share, or 10.15%, to close at $32.12 per share on March 21, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.   

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

 

The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

    

[Click here for information about joining the class action]    

On February 21, 2024, Community Health disclosed in its Annual Report for 2023 that it was under investigation by the U.S. Department of Justice (“DOJ”).  The Company revealed that it had received a Civil Investigative Demand from the DOJ on January 11, 2024, seeking “documents and information relating to a variety of subjects, including practices and procedures related to utilization review, inpatient admissions and inpatient dialysis at [the Company's] hospitals.” 

On this news, Community Health’s stock price fell $1.14 per share, or 28.2%, to close at $2.90 per share on February 21, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.   

Attorney advertising.  Prior results do not guarantee similar outcomes.    

Pomerantz Law Firm Investigates Claims On Behalf of Investors of CI&T Inc. - CINT

Pomerantz LLP is investigating claims on behalf of investors of  CI&T Inc. (“CI&T” or the “Company”) (NYSE: CINT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

 

The investigation concerns whether CI&T and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

 

[Click here for information about joining the class action]

           

On March 7, 2024, CI&T issued a press release stating that the Company had “identified certain non-cash accounting errors related to deferred income accounting for tax-deductible goodwill, as required under IFRS – International Financial Reporting Standard (‘IFRS’).”  Accordingly, CI&T advised that “(i) the Company’s audited consolidated financial statements as of and for the year ended December 31, 2022, included in its annual report on Form 20-F for the year ended December 31, 2022 filed with the United States Securities and Exchange Commission (‘SEC’) on March 28, 2023, and (ii) the Company’s unaudited condensed consolidated interim financial statements as of and for the periods ended March 31, 2023, June 30, 2023 and September 30, 2023, each previously furnished to the SEC on a current report on Form 6-K, should no longer be relied upon[.]” 

 

On this news, CI&T’s stock price fell $0.44 per share, or 9.89%, to close at $4.01 per share on March 7, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bridge Investment Group Holdings Inc. - BRDG

Pomerantz LLP is investigating claims on behalf of investors of Bridge Investment Group Holdings Inc. (“Bridge” or the “Company”) (NYSE: BRDG).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

           

The investigation concerns whether Bridge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]    

On February 21, 2024, Bridge issued a press release reporting its financial results for the fourth quarter and full year 2023.  Among other items, Bridge reported a net loss of $87.4 million for the year, citing “volatility within commercial real estate markets” and stating that “[f]und management fees for the quarter . . . were negatively impacted by $5.7 million related to Bridge Office Fund I fees that were deemed uncollectible due to market headwinds within the broader office sector.” 

On this news, Bridge’s stock price fell $1.38 per share, or 15.83%, to close at $7.34 per share on February 22, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.   

Attorney advertising.  Prior results do not guarantee similar outcomes.    

 

 

 

 

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mister Car Wash, Inc. - MCW

Pomerantz LLP is investigating claims on behalf of investors of Mister Car Wash, Inc. (“MCW” or the “Company”) (NYSE: MCW).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether MCW and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.   

[Click here for information about joining the class action]  

On February 21, 2024, MCW issued a press release announcing its fourth quarter and fiscal year 2023 financial results.  Among other items, MCW reported revenue of $230.1 million, missing consensus estimates by $0.32 million. 

On this news, MCW’s stock price fell $0.90 per share, or 10.34%, to close at $7.80 per share on February 22, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.  

Attorney advertising.  Prior results do not guarantee similar outcomes.   

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

 

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]    

On February 14, 2024, Biogen disclosed receipt of a subpoena from the U.S. Department of Justice seeking information about its “business operations in several foreign countries.” 

On this news, Biogen's stock price fell $5.91 per share, or 2.6%, to close at $220.74 per share on February 14, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.   

Attorney advertising.  Prior results do not guarantee similar outcomes.    

 

Pomerantz Law Firm Investigates Claims on Behalf of Investors of World Acceptance Corporation - WRLD

Pomerantz LLP is investigating claims on behalf of investors of World Acceptance Corporation (“WAC” or the “Company”) (NASDAQ: WRLD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

 

The investigation concerns whether WAC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]    

On February 23, 2024, the Consumer Financial Protection Bureau announced that risks surrounding World Acceptance Corporation’s conduct warranted the need for federal supervision.  

On this news, WAC’s stock price fell $11.23 per share, or 8.65%, to close at $118.59 per share on February 26, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.   

Attorney advertising.  Prior results do not guarantee similar outcomes.    

 

 

Pomerantz Law Firm Investigates Claims On Behalf of Investors of UnitedHealth Group Incorporated - UNH

Pomerantz LLP is investigating claims on behalf of investors of UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

The investigation concerns whether UnitedHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

               

On February 27, 2024, The Wall Street Journal (“WSJ”) reported that the U.S. Department of Justice (“DOJ”) has launched an antitrust investigation into UnitedHealth.  Specifically, the WSJ reported that DOJ investigators have been interviewing healthcare industry representatives in sectors where UnitedHealth competes to determine the possible impacts of acquisitions made through its health services arm, Optum.

On this news, UnitedHealth’s stock price fell $27.04 per share, or 5.15%, over the following two trading sessions, to close at $498.28 per share on February 28, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes. 

 

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luminar Technologies, Inc. - LAZR

Pomerantz LLP is investigating claims on behalf of investors of Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

 

The investigation concerns whether Luminar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

 

[Click here for information about joining the class action]

               

On or around March 17, 2023, media outlets reported that the semiconductor developer Lidwave had accused Luminar of attempting to pass off a Lidwave chip as Luminar’s own technology after showing an image of the processor at a recent investor conference and in materials on its website, threatening Luminar with legal action.  Luminar subsequently removed the images in question from its investor presentation and website. 

 

On this news, Luminar’s stock price fell $0.68 per share, or 8.02%, to close at $7.80 per share on March 20, 2023.  Then, on February 27, 2024, Luminar issued a press release reporting its fourth quarter and full-year 2023 financial results.  Among other items, Luminar reported non-GAAP earnings per share of -$0.20 for the quarter, missing consensus estimates by $0.01, and revenue of $22.11 million, missing consensus estimates by $5.19 million. 

 

On this news, Luminar’s stock price fell $0.12 per share, or 4.8%, to close at $2.38 per share on February 28, 2024.

 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

 

Attorney advertising.  Prior results do not guarantee similar outcomes.